VSG - Visiomed Group
- Thread starter Cris
- Start date
-
- Tags
- visiomed group vsg
- Joined
- 23 March 2005
- Posts
- 1,943
- Reactions
- 1
surelle said:
including our bank balances
- Joined
- 23 March 2005
- Posts
- 1,943
- Reactions
- 1
In my opinion this report is 1000% better then the one released last week.
To quote Big Kev "I'm excited"!!!!
Visiomed Group Ltd
ASX Code : VSG
Shares on Issue : 296 million Major Shareholders
Market Capitalisation (@ 2c) - $A6mill (~$3.5mill euro) Directors 15.5%
Cash at Bank: $A.95 million (no debt) Top 40 holders 49.4%
Visiomed develops and commercializes innovative technologies for improved medication delivery and adherence, helping people live normal, healthy and active lives. During the past 12 months the company has significantly repositioned itself focusing on the large and growing
US$28 billion worldwide respiratory diseases market.
The worldwide market for spacers and inhaled drug delivery devices is in excess of US$6B.
Visiomed's initial product, the Funhaler asthma spacer, has captured approximately 6% of Australian market within first 6 months of release; assuming proposed acquisition completed, the company anticipates similar uptake can be achieved in US, EU and Japan markets yielding earnings of estimated US$4 million within 36 months
The Company's product has been demonstrated to increase compliance to prescription medication which could increase revenues to pharmaceutical companies by greater than US$1B annually. Hence successful introduction of product makes Visiomed a likely takeover
target.
The only incentive "spacer" device designed specifically for children. Assists in the delivery of inhaled medication for respiratory diseases (such as asthma). Clinically demonstrated to improve compliance to prescribed medication by 38% and successful medication of children by 60%.
Spacers improve drug delivery, reduce the side effects of medications and are recommended by all major medical organizations. Spacer market forecast to more than triple over the next 5 years.
Market for asthma spacers and similar products worth US$2.8 billion in Australia, USA, the EU and Japan alone. Asthma is the most common chronic childhood disease, affecting 12 - 16% of all children.
Total market for respiratory disease medication delivery devices is US$6.2 billion, representing 485 million affected people. This excludes other new opportunities for inhaled medication, including diabetes, cardiovascular hypertension and other anti-virals and anti-biotics (e.g., HIV, birdflu, herpes, etc.) which represents another US$7.4
billion market.
Within 6 months of release the Funhaler has captured approximately 6% of the Australian spacer market. The company believes similar uptake rates are achievable in the US, European and Japanese markets. Based on published asthma rates and spacer sales, it is estimated that the market for spacers is less than 20% saturated.
Visiomed is undertaking an acquisition of a major supplier of spacers in Australia which has in place a licensing agreement with a leading US-based devices company in the areas of respiratory and sleep apnea. The strategic partnership will give the company accelerated access to worldwide markets. The acquisition will see Visiomed profitable in 2006 / 07 from existing business alone and the dominant player in the Australian spacer market.
The Company has been granted all regulatory approvals in the US (FDA 510), Australia
(TGA) and Europe (CE mark) hence is cleared to commence marketing and sales in these major markets.
Visiomed holds key patents for inhaled drug delivery and improved compliance. Patented
and proprietary technology includes low flow rate valves for the delivery of medication and the incorporation of incentive and feedback mechanisms to drug delivery devices.
Company's core patented technologies applicable to any inhaled drug delivery device. Compliance is key issue in healthcare: less than 45% of patients adhere to their prescribed medication plan and less than approximately 40% of prescribed asthma medication is actually purchased. Improved compliance directly translates to improved healthcare and increased pharmaceutical revenues. The Company's products target improved compliance; the Funhaler has been clinically proven to increase compliance by 38% hence the company is a likely takeover target.
Obvious synergies with licensing partner, including distribution channels, product development and corporate partnership. Distribution discussions underway in Europe and the US already.
Excellent international growth prospects from rapidly growing drug delivery device market.
Large percent of major drugs now off-patent hence generic pharmaceutical companies need differentiation and large pharmaceutical companies need to extend life of patented drugs - hence reformulations for new & improved drug delivery devices with inhaled
delivery the pathway of choice for insulin, anti-virals, antibiotics, hypertensives, etc.
High margin product. Currently completing manufacturing upgrade which will yield high volume, low cost production with gross margins in excess of 70%. Further cost savings realizable in manufacturing, marketing and distribution with acquisition.
Excellent management with strong track record
William F. Dolphin, Ph.D., CEO. Over 20 years of senior executive experience in the med-tech and technology industries. Dr. Dolphin was previously CEO of a U.S. medical technology company which achieved 5 year growth over 6000% with 20% earnings, has been the recipient of prestigious Product Innovation Award from Frost & Sullivan, and was twice recipient of the US National Institutes of Health Research Service Award. Dr Dolphin joined the Company in April 2005.
Summary
High margin product targeting large and growing respiratory disease market (greater than US$6B)
Addresses major issue in healthcare, i.e. compliance. Improved compliance directly translates to
increased revenues to pharmaceutical companies; hence Visiomed is likely takeover target.
Company is significantly undervalued; on cusp of major worldwide launch with patents and all regulatory approvals (US 510K, CE mark) in place.
Experienced management with proven track record.
To quote Big Kev "I'm excited"!!!!
Visiomed Group Ltd
ASX Code : VSG
Shares on Issue : 296 million Major Shareholders
Market Capitalisation (@ 2c) - $A6mill (~$3.5mill euro) Directors 15.5%
Cash at Bank: $A.95 million (no debt) Top 40 holders 49.4%
Visiomed develops and commercializes innovative technologies for improved medication delivery and adherence, helping people live normal, healthy and active lives. During the past 12 months the company has significantly repositioned itself focusing on the large and growing
US$28 billion worldwide respiratory diseases market.
The worldwide market for spacers and inhaled drug delivery devices is in excess of US$6B.
Visiomed's initial product, the Funhaler asthma spacer, has captured approximately 6% of Australian market within first 6 months of release; assuming proposed acquisition completed, the company anticipates similar uptake can be achieved in US, EU and Japan markets yielding earnings of estimated US$4 million within 36 months
The Company's product has been demonstrated to increase compliance to prescription medication which could increase revenues to pharmaceutical companies by greater than US$1B annually. Hence successful introduction of product makes Visiomed a likely takeover
target.
The only incentive "spacer" device designed specifically for children. Assists in the delivery of inhaled medication for respiratory diseases (such as asthma). Clinically demonstrated to improve compliance to prescribed medication by 38% and successful medication of children by 60%.
Spacers improve drug delivery, reduce the side effects of medications and are recommended by all major medical organizations. Spacer market forecast to more than triple over the next 5 years.
Market for asthma spacers and similar products worth US$2.8 billion in Australia, USA, the EU and Japan alone. Asthma is the most common chronic childhood disease, affecting 12 - 16% of all children.
Total market for respiratory disease medication delivery devices is US$6.2 billion, representing 485 million affected people. This excludes other new opportunities for inhaled medication, including diabetes, cardiovascular hypertension and other anti-virals and anti-biotics (e.g., HIV, birdflu, herpes, etc.) which represents another US$7.4
billion market.
Within 6 months of release the Funhaler has captured approximately 6% of the Australian spacer market. The company believes similar uptake rates are achievable in the US, European and Japanese markets. Based on published asthma rates and spacer sales, it is estimated that the market for spacers is less than 20% saturated.
Visiomed is undertaking an acquisition of a major supplier of spacers in Australia which has in place a licensing agreement with a leading US-based devices company in the areas of respiratory and sleep apnea. The strategic partnership will give the company accelerated access to worldwide markets. The acquisition will see Visiomed profitable in 2006 / 07 from existing business alone and the dominant player in the Australian spacer market.
The Company has been granted all regulatory approvals in the US (FDA 510), Australia
(TGA) and Europe (CE mark) hence is cleared to commence marketing and sales in these major markets.
Visiomed holds key patents for inhaled drug delivery and improved compliance. Patented
and proprietary technology includes low flow rate valves for the delivery of medication and the incorporation of incentive and feedback mechanisms to drug delivery devices.
Company's core patented technologies applicable to any inhaled drug delivery device. Compliance is key issue in healthcare: less than 45% of patients adhere to their prescribed medication plan and less than approximately 40% of prescribed asthma medication is actually purchased. Improved compliance directly translates to improved healthcare and increased pharmaceutical revenues. The Company's products target improved compliance; the Funhaler has been clinically proven to increase compliance by 38% hence the company is a likely takeover target.
Obvious synergies with licensing partner, including distribution channels, product development and corporate partnership. Distribution discussions underway in Europe and the US already.
Excellent international growth prospects from rapidly growing drug delivery device market.
Large percent of major drugs now off-patent hence generic pharmaceutical companies need differentiation and large pharmaceutical companies need to extend life of patented drugs - hence reformulations for new & improved drug delivery devices with inhaled
delivery the pathway of choice for insulin, anti-virals, antibiotics, hypertensives, etc.
High margin product. Currently completing manufacturing upgrade which will yield high volume, low cost production with gross margins in excess of 70%. Further cost savings realizable in manufacturing, marketing and distribution with acquisition.
Excellent management with strong track record
William F. Dolphin, Ph.D., CEO. Over 20 years of senior executive experience in the med-tech and technology industries. Dr. Dolphin was previously CEO of a U.S. medical technology company which achieved 5 year growth over 6000% with 20% earnings, has been the recipient of prestigious Product Innovation Award from Frost & Sullivan, and was twice recipient of the US National Institutes of Health Research Service Award. Dr Dolphin joined the Company in April 2005.
Summary
High margin product targeting large and growing respiratory disease market (greater than US$6B)
Addresses major issue in healthcare, i.e. compliance. Improved compliance directly translates to
increased revenues to pharmaceutical companies; hence Visiomed is likely takeover target.
Company is significantly undervalued; on cusp of major worldwide launch with patents and all regulatory approvals (US 510K, CE mark) in place.
Experienced management with proven track record.
- Joined
- 23 March 2005
- Posts
- 1,943
- Reactions
- 1
About bloody time!
- Joined
- 23 March 2005
- Posts
- 1,943
- Reactions
- 1
Trading Halt requested until Thursday.
hopefully this is the beginning of the good times we've been promised for so long...
hopefully this is the beginning of the good times we've been promised for so long...
- Joined
- 23 March 2005
- Posts
- 1,943
- Reactions
- 1
you still in this one Surelle??
I don't know why I keep torturing myself...
I don't know why I keep torturing myself...
sam76 said:you still in this one Surelle??
I don't know why I keep torturing myself...
yes sadly, I don't know why, but I still believe in it's potential - in theory, this company, with the purchase of Breath-a-tech, should start to make some real progress, due to the increased cases of asthma and CPD, but go figure, every time there is some north bound movement, it falls over again.
Those are who selling out have obviously lost faith (which in hindsight, I should have done ages ago ) so the company needs to pull one mighty big rabbit out of their hat and produce some figures to reinstate their status.
I'm hanging on for a little while longer and will re-assess but until then, my head is getting sorer each day.
How about you?? are you still holding and what r ur thoughts??
:
- Joined
- 23 March 2005
- Posts
- 1,943
- Reactions
- 1
surelle said:yes sadly, I don't know why, but I still believe in it's potential - in theory, this company, with the purchase of Breath-a-tech, should start to make some real progress, due to the increased cases of asthma and CPD, but go figure, every time there is some north bound movement, it falls over again.
Those are who selling out have obviously lost faith (which in hindsight, I should have done ages ago ) so the company needs to pull one mighty big rabbit out of their hat and produce some figures to reinstate their status.
I'm hanging on for a little while longer and will re-assess but until then, my head is getting sorer each day.
How about you?? are you still holding and what r ur thoughts??
I'm still hanging in there as well. The only thing left is for VSG to do is to start selling the actual product!.
The aquistion means instant revenue as well as an established entry into the market.
I really want to bail as I feel so let down by this Company, but i think that a series of + announcements are only around the corner.
Money in the bank.
A proven product.
All approvals stamped (FDA and EUROPE).
Local Market Success.
MASSIVE Internation market share potential
Low manufacturing costs and high profit margin.
And Kids Love it!!!!
I don't know why I'm still in... ah yes... because it has a very good chance of making me money (albeit slowly)
Visiomed develops and commercializes innovative technologies for improved medication delivery and adherence, helping people live normal, healthy and active lives. During the past 12 months the company has significantly repositioned itself focusing on the large and growing
US$28 billion worldwide respiratory diseases market.
The worldwide market for spacers and inhaled drug delivery devices is in excess of US$6B.
Visiomed's initial product, the Funhaler asthma spacer, has captured approximately 6% of Australian market within first 6 months of release; assuming proposed acquisition completed, the company anticipates similar uptake can be achieved in US, EU and Japan markets yielding earnings of estimated US$4 million within 36 months
The Company's product has been demonstrated to increase compliance to prescription medication which could increase revenues to pharmaceutical companies by greater than US$1B annually. Hence successful introduction of product makes Visiomed a likely takeover
target.
The only incentive "spacer" device designed specifically for children. Assists in the delivery of inhaled medication for respiratory diseases (such as asthma). Clinically demonstrated to improve compliance to prescribed medication by 38% and successful medication of children by 60%.
Spacers improve drug delivery, reduce the side effects of medications and are recommended by all major medical organizations. Spacer market forecast to more than triple over the next 5 years.
Market for asthma spacers and similar products worth US$2.8 billion in Australia, USA, the EU and Japan alone. Asthma is the most common chronic childhood disease, affecting 12 - 16% of all children.
Total market for respiratory disease medication delivery devices is US$6.2 billion, representing 485 million affected people. This excludes other new opportunities for inhaled medication, including diabetes, cardiovascular hypertension and other anti-virals and anti-biotics (e.g., HIV, birdflu, herpes, etc.) which represents another US$7.4
billion market.
Within 6 months of release the Funhaler has captured approximately 6% of the Australian spacer market. The company believes similar uptake rates are achievable in the US, European and Japanese markets. Based on published asthma rates and spacer sales, it is estimated that the market for spacers is less than 20% saturated.
Visiomed is undertaking an acquisition of a major supplier of spacers in Australia which has in place a licensing agreement with a leading US-based devices company in the areas of respiratory and sleep apnea. The strategic partnership will give the company accelerated access to worldwide markets. The acquisition will see Visiomed profitable in 2006 / 07 from existing business alone and the dominant player in the Australian spacer market.
The Company has been granted all regulatory approvals in the US (FDA 510), Australia
(TGA) and Europe (CE mark) hence is cleared to commence marketing and sales in these major markets.
Visiomed holds key patents for inhaled drug delivery and improved compliance. Patented
and proprietary technology includes low flow rate valves for the delivery of medication and the incorporation of incentive and feedback mechanisms to drug delivery devices.
Company's core patented technologies applicable to any inhaled drug delivery device. Compliance is key issue in healthcare: less than 45% of patients adhere to their prescribed medication plan and less than approximately 40% of prescribed asthma medication is actually purchased. Improved compliance directly translates to improved healthcare and increased pharmaceutical revenues. The Company's products target improved compliance; the Funhaler has been clinically proven to increase compliance by 38% hence the company is a likely takeover target.
Obvious synergies with licensing partner, including distribution channels, product development and corporate partnership. Distribution discussions underway in Europe and the US already.
Excellent international growth prospects from rapidly growing drug delivery device market.
Large percent of major drugs now off-patent hence generic pharmaceutical companies need differentiation and large pharmaceutical companies need to extend life of patented drugs - hence reformulations for new & improved drug delivery devices with inhaled
delivery the pathway of choice for insulin, anti-virals, antibiotics, hypertensives, etc.
High margin product. Currently completing manufacturing upgrade which will yield high volume, low cost production with gross margins in excess of 70%. Further cost savings realizable in manufacturing, marketing and distribution with acquisition.
Excellent management with strong track record
William F. Dolphin, Ph.D., CEO. Over 20 years of senior executive experience in the med-tech and technology industries. Dr. Dolphin was previously CEO of a U.S. medical technology company which achieved 5 year growth over 6000% with 20% earnings, has been the recipient of prestigious Product Innovation Award from Frost & Sullivan, and was twice recipient of the US National Institutes of Health Research Service Award. Dr Dolphin joined the Company in April 2005.
Summary
High margin product targeting large and growing respiratory disease market (greater than US$6B)
Addresses major issue in healthcare, i.e. compliance. Improved compliance directly translates to
increased revenues to pharmaceutical companies; hence Visiomed is likely takeover target.
Company is significantly undervalued; on cusp of major worldwide launch with patents and all regulatory approvals (US 510K, CE mark) in place.
Experienced management with proven track record.
- Joined
- 23 March 2005
- Posts
- 1,943
- Reactions
- 1
Last Price +/- % Open High Volume
$0.0130 $0.0020 18.2% 0.0110 0.0130 15,456,391
At last!
hopefully some + announcents next week will solidfy the price rise.
$0.0130 $0.0020 18.2% 0.0110 0.0130 15,456,391
At last!
hopefully some + announcents next week will solidfy the price rise.
- Joined
- 23 March 2005
- Posts
- 1,943
- Reactions
- 1
i was so close to getting out as well
- Joined
- 23 March 2005
- Posts
- 1,943
- Reactions
- 1
having a nice little run this morning.
VSG are due to announce distributors for it's 3 biggest markets; US, Japan and the UK very soon.
Their last quarterly was fantastic - in fact it was the best one in the 5 odd years I've been holding.
Sales up 250% over the quarter (last quarter is traditionally the slowest for spacers as well)
initial commitments for over $1,000,000 worth of sales from existing distributors.
Patents in China and US completed.
High volume low cost manufacturing plants completed.
New management
All things point to a great little company! (we hope)
VSG are due to announce distributors for it's 3 biggest markets; US, Japan and the UK very soon.
Their last quarterly was fantastic - in fact it was the best one in the 5 odd years I've been holding.
Sales up 250% over the quarter (last quarter is traditionally the slowest for spacers as well)
initial commitments for over $1,000,000 worth of sales from existing distributors.
Patents in China and US completed.
High volume low cost manufacturing plants completed.
New management
All things point to a great little company! (we hope)
- Joined
- 23 March 2005
- Posts
- 1,943
- Reactions
- 1
Ex GSK Sales Manager announced to the market yesterday - fantastic news!
Trading Halt today???
Either cap raising (doubt it)
or big distributor signed on (more likely)
All signs are pointing to a massive turn around for VSG
Surelle, are you there? What are your thoughts?
Trading Halt today???
Either cap raising (doubt it)
or big distributor signed on (more likely)
All signs are pointing to a massive turn around for VSG
Surelle, are you there? What are your thoughts?
yes, I'm still here
why, I don't know....oh yes I do, I have some money invested in this !!!!! I tend to agree with you, they have a new sales manager and he's come in with some (hopefully) grand ideas and they need some MORE cash to get on with it....and in principal i'm excited but i don't want to get too excited again......hey, maybe now they have the guy from the opposition working for them, maybe the opposition has made them a takeover offer too good to refuse.... (what a way to start a rumour !!!)I hope you are right about those signs Sam coz
LOL - fingers crossed
Similar threads
